US 11,833,136 B2
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Jennifer L. R. Freeman, Winston-Salem, NC (US); and Maria Carmen Valcarce Lopez, Oak Ridge, NC (US)
Assigned to VTV THERAPEUTICS LLC, High Point, NC (US)
Filed by vTv Therapeutics LLC, High Point, NC (US)
Filed on Feb. 18, 2021, as Appl. No. 17/178,402.
Application 17/178,402 is a continuation of application No. 16/741,224, filed on Jan. 13, 2020, granted, now 10,952,993.
Application 16/741,224 is a continuation of application No. PCT/US2019/036227, filed on Jun. 10, 2019.
Claims priority of provisional application 62/857,753, filed on Jun. 5, 2019.
Claims priority of provisional application 62/683,772, filed on Jun. 12, 2018.
Prior Publication US 2021/0169857 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/426 (2006.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/426 (2013.01) [A61K 9/0053 (2013.01); A61P 3/10 (2018.01)] 20 Claims
 
1. A method of reducing the incidence of hypoglycemic events in a human subject on insulin therapy, the method comprising administering 400 mg/day to 1200 mg/day of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof to the human subject on insulin therapy, wherein the {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof is orally administered once a day, and wherein the incidence of hypoglycemic events in the human subject is reduced over a period of time relative to baseline.